http://bakeridi.technologypublisher.comBe the first to know about the latest inventions and technologies available from Baker IDI Heart and Diabetes Institute Holdings Ltden-USSun, 17 May 2026 23:35:28 GMTSun, 06 Mar 2016 17:46:31 GMThttp://blogs.law.harvard.edu/tech/rssceline.latouche@bakeridi.edu.auCopyright 2026, Baker IDI Heart and Diabetes Institute Holdings LtdTEC-B-2011/0059http://bakeridi.technologypublisher.com/technology/21503Sun, 06 Mar 2016 17:46:31 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/21503TEC-B-2014/0002http://bakeridi.technologypublisher.com/technology/20679Atherosclerosis is the single most common cause of cardiovascular disease and is the major contributor to the development of angina, heart attacks, congestive heart failure, peripheral vascular disease and stroke. Despite the introduction of statin based therapy to reduce levels of plasma LDL-cholesterol, the epidemic of cardiovascular disease claims over 40,000 Australian lives and costs the health system approximately $6 billion per year. New approaches are required if we are to further reduce the burden of cardiovascular disease.Baker IDI researchers have identified negative associations of...Thu, 29 Oct 2015 17:41:11 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/20679TEC-B-2011/0062http://bakeridi.technologypublisher.com/technology/20678Professor Peter's group at Baker IDI has unique expertise in molecular imaging technology identifying different components of vulnerable atherosclerotic plaques. This group is developing a highly sensitive narrow-range wavelength fluorescence catheter. Vulnerable atherosclerotic plaques are the most important cause of cardiovascular mortality and morbidity worldwide. Detection of these plaques has an enormous health and economic potential. Our studies have shown conclusive results demonstrating fluorescence imaging could be used to detect vulnerable plaques and differentiate these from stable ...Thu, 29 Oct 2015 17:29:52 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/20678TEC-B-2010/0072http://bakeridi.technologypublisher.com/technology/20677Atherosclerosis is a chronic, inflammatory disease driven by the continuous emigration of monocytes into the vessel wall. CD40L is an established marker and mediator of chronic inflammatory diseases such as atherosclerosis. While anti-CD40L treatment generated promising results in clinical trials, elevated thrombembolic complications prohibited the pursuit of this strategy. Baker IDI researchers previously reported that CD40L mediates atherogenesis independently of CD40 in mice, proposing a novel interaction with the leukocyte integrin Mac-1. Targeting of CD40L/Mac-1 binding with an inhibitory...Thu, 29 Oct 2015 17:22:25 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/20677TEC-B-2006/0085http://bakeridi.technologypublisher.com/technology/20676Baker IDI researchers, in collaboration with researchers at the University of Kiel, have synthesised a first-in-class therapy for insulin sensitisation in diabetic patients to address the treatment gap. The biological agent, IC7, underwent preclinical optimisation to achieve a daily, injectable treatment regime for those with T2D who are already faced with the option of insulin injections to manage the progressive nature of their disease. CNTF has anti-obesity central and peripheral effects. It was developed as Axokine by Regeneron Ltd but failed in phase III trials due to antibodies developin...Thu, 29 Oct 2015 17:08:13 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/20676TEC-B-2009/1074http://bakeridi.technologypublisher.com/technology/20675Baker IDI researchers have designed a potent natriuretic peptide that has the potential not only to provide a treatment for HF patients in hospital, but also for stable HF patients after discharge. Natriuretic peptides are normally released by a failing heart to reduce the symptoms of heart failure through multiple actions: increasing blood volume, reducing cardiac contractility and lowering cardiac output. Current treatments for HF still elicit many side effects, often treat only single symptoms, and rarely address the progression of the disease. After identifying the novel NP, the investigat...Thu, 29 Oct 2015 16:52:10 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/20675TEC-B-2011/0048http://bakeridi.technologypublisher.com/technology/10109Sun, 26 Aug 2012 22:05:19 GMTceline.latouche@bakeridi.edu.auhttp://bakeridi.technologypublisher.com/technology/10109